About us Pricing ContactSubscribe

C

Caroline Robert

Université de franche-comtéORCID https://orcid.org/0000-0002-9493-0238

h-index

—

Publications

—

Citations

—

i10-index

—

Impact (2-yr)

—

Top Publications

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine201015,037 citations

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

New England Journal of Medicine20117,653 citations

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology20172,321 citations

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Journal of Clinical Oncology20152,105 citations

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

European Journal of Cancer20162,094 citations

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

The Lancet Oncology20151,554 citations

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of Oncology20171,280 citations

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology20221,025 citations

Removal of C.I. Basic Green 4 (Malachite Green) from aqueous solutions by adsorption using cyclodextrin-based adsorbent: Kinetic and equilibrium studies

Separation and Purification Technology2006966 citations

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Annals of Oncology2019928 citations

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Annals of Oncology2015885 citations